Aldeyra Therapeutics Granted Orphan Status by European Medicines Agency for ADX-2191 in Treating Primary Large B-Cell Lymphomas in Immune-Privileged Areas, Such as Primary Vitreoretinal Lymphoma
Orphan Designation Granted: Aldeyra Therapeutics announced that the European Medicines Agency has granted Orphan Designation for ADX-2191, a methotrexate intravitreal injection, for treating primary large B-Cell lymphomas of immune-privileged sites, including primary vitreoretinal lymphoma.
Current Treatment Landscape: There are no approved treatments for primary vitreoretinal lymphoma, which affects 100 to 200 patients annually in the EU, and current care involves off-label compounded formulations of methotrexate.
Clinical Trial Plans: A clinical trial comparing cancer cell clearance after different administration frequencies of ADX-2191 is set to begin in late 2025, following FDA agreement on the protocol.
About Aldeyra Therapeutics: The company focuses on developing innovative therapies for immune-mediated and metabolic diseases, with ADX-2191 being part of their efforts to treat rare retinal diseases.
Trade with 70% Backtested Accuracy
Analyst Views on ALDX
About ALDX
About the author
Surge in Options Trading Volume for ACMR and ALDX
- ACMR Options Volume: ACM Research Inc (ACMR) has seen an options trading volume of 8,259 contracts today, representing approximately 825,900 shares, which is about 53.7% of its average daily trading volume of 1.5 million shares over the past month, indicating heightened market interest in its future performance.
- High Frequency Trading: Within ACMR, the $80 strike call option has been particularly active, with 2,496 contracts traded today, equating to approximately 249,600 shares, suggesting strong bullish sentiment among investors at this price level.
- ALDX Options Activity: Concurrently, Aldeyra Therapeutics Inc (ALDX) has recorded an options trading volume of 4,196 contracts, representing around 419,600 shares, which is approximately 53.3% of its average daily trading volume of 787,615 shares over the past month, reflecting investor interest in its stock.
- ALDX High Frequency Trading: For ALDX, the $4 strike put option has seen a trading volume of 2,473 contracts, approximately 247,300 shares, indicating bearish sentiment in the market, possibly linked to uncertainties surrounding the company's future.
Healthcare Stocks with Strong Earnings Momentum Earn A+ EPS Revision Grades
- Investor Attention: As the earnings season unfolds, mid to low market capitalization healthcare stocks are drawing investor attention due to their strong earnings momentum, indicating growing market confidence in this sector.
- Analyst Expectations: The EPS Revision Grade reflects the trend in analyst earnings estimates, with A+ ratings indicating optimistic projections for future performance, potentially driving stock prices higher.
- List of A+ Rated Stocks: Currently, companies such as Aldeyra Therapeutics, Altimmune, Annovis Bio, and Assertio Holdings have received A+ EPS Revision Grades, showcasing their strong performance in the eyes of analysts.
- Market Strategy Impact: These A+ rated healthcare stocks are likely to attract more investor interest, potentially triggering positive sentiment towards the healthcare sector as a whole, thereby enhancing the performance of related ETFs.
FDA Prolongs Review Period for Aldeyra's Drug for Dry Eye Disease
FDA Action on Aldeyra's NDA: The FDA has extended the target action date for Aldeyra Therapeutics' New Drug Application (NDA) for reproxalap, a treatment for dry eye disease, to March 16, 2026, following a request for additional clinical data.
Clinical Trial Results: The field trial for reproxalap did not meet its primary endpoint of improving dry eye symptoms compared to the vehicle control, despite being supportive of the drug's activity.
Regulatory Review Process: Aldeyra submitted a Clinical Study Report (CSR) as a major amendment to the NDA, and the FDA plans to communicate any proposed labeling requests by February 16, 2026, if no major deficiencies are found.
Stock Market Reaction: Following the FDA's announcement, Aldeyra Therapeutics' stock fell by 12.1% to $3.99, with a further decline of 1.5% in premarket trading.
B. Riley Financial Shares Surge Approximately 25%; Check Out 20 Stocks Making Moves in Premarket Trading
B. Riley Financial Performance: B. Riley Financial Inc reported a significant turnaround with earnings of $4.50 per share for Q2, compared to a loss of $14.35 per share a year ago, and sales increased to $225.302 million from $94.885 million, leading to a 25% rise in share price during pre-market trading.
Pre-Market Stock Movements: Several stocks experienced notable pre-market trading movements, with Biodexa Pharmaceuticals gaining 51.4% and Venus Concept surging 31.1%, while Radiopharm Theranostics saw a sharp decline of 39.8%.
Other Notable Gainers: Other stocks that rose in pre-market trading included Uniqure NV (+14.1%), Adagio Medical Holdings (+11.7%), and Sunrise New Energy (+10.5%), reflecting a mix of recovery and growth in various sectors.
Significant Losers: Stocks that faced declines included iRobot Corp, which fell 23.2% after filing for Chapter 11 bankruptcy, and Saverone 2014 Ltd, which tumbled 37.8% following a previous gain, indicating volatility in the market.
Aldeyra Shares Fall as FDA Postpones Review of Key Drug Marketing Application
FDA Review Delay: Aldeyra Therapeutics experienced a ~12% drop in premarket trading after announcing a delay in the FDA review of its resubmitted marketing application for reproxalap, with a new target action date set for March 16, 2026.
Clinical Study Report Submission: The delay follows the company's submission of a clinical study report for a dry eye disease trial, which the FDA deemed a major amendment to the new drug application (NDA).
Trial Results: The trial did not meet its primary goal of improving dry eye symptoms, and Aldeyra submitted the safety data to the FDA in August.
Prospective Labeling: Despite the delay, the FDA has provided a draft of the prospective label for reproxalap, indicating that if no major deficiencies are found, the company will receive proposed labeling requests and potential postmarketing requirements.
FDA Prolongs Review Period for Aldeyra's Reproxalap NDA for Dry Eye Disease
FDA Extension: The FDA has extended the PDUFA target action date for Aldeyra Therapeutics' NDA for reproxalap to March 16, 2026, following a major amendment related to the Clinical Study Report.
Clinical Trial Results: The field trial for reproxalap showed activity compared to a vehicle but did not meet its primary endpoint of symptom improvement, leading to the submission of additional data to the FDA.
Labeling and Requirements: The FDA provided a draft product label to Aldeyra, indicating that proposed labeling changes and potential postmarketing requirements will be communicated by February 16, 2026, if no major deficiencies are found.
Stock Performance: Aldeyra's stock closed at $3.99, down 12.11%, and further declined to $3.32 in after-hours trading, reflecting investor concerns following the news.
Surge in Options Trading Volume for ACMR and ALDX
- ACMR Options Volume: ACM Research Inc (ACMR) has seen an options trading volume of 8,259 contracts today, representing approximately 825,900 shares, which is about 53.7% of its average daily trading volume of 1.5 million shares over the past month, indicating heightened market interest in its future performance.
- High Frequency Trading: Within ACMR, the $80 strike call option has been particularly active, with 2,496 contracts traded today, equating to approximately 249,600 shares, suggesting strong bullish sentiment among investors at this price level.
- ALDX Options Activity: Concurrently, Aldeyra Therapeutics Inc (ALDX) has recorded an options trading volume of 4,196 contracts, representing around 419,600 shares, which is approximately 53.3% of its average daily trading volume of 787,615 shares over the past month, reflecting investor interest in its stock.
- ALDX High Frequency Trading: For ALDX, the $4 strike put option has seen a trading volume of 2,473 contracts, approximately 247,300 shares, indicating bearish sentiment in the market, possibly linked to uncertainties surrounding the company's future.
Healthcare Stocks with Strong Earnings Momentum Earn A+ EPS Revision Grades
- Investor Attention: As the earnings season unfolds, mid to low market capitalization healthcare stocks are drawing investor attention due to their strong earnings momentum, indicating growing market confidence in this sector.
- Analyst Expectations: The EPS Revision Grade reflects the trend in analyst earnings estimates, with A+ ratings indicating optimistic projections for future performance, potentially driving stock prices higher.
- List of A+ Rated Stocks: Currently, companies such as Aldeyra Therapeutics, Altimmune, Annovis Bio, and Assertio Holdings have received A+ EPS Revision Grades, showcasing their strong performance in the eyes of analysts.
- Market Strategy Impact: These A+ rated healthcare stocks are likely to attract more investor interest, potentially triggering positive sentiment towards the healthcare sector as a whole, thereby enhancing the performance of related ETFs.
FDA Prolongs Review Period for Aldeyra's Drug for Dry Eye Disease
FDA Action on Aldeyra's NDA: The FDA has extended the target action date for Aldeyra Therapeutics' New Drug Application (NDA) for reproxalap, a treatment for dry eye disease, to March 16, 2026, following a request for additional clinical data.
Clinical Trial Results: The field trial for reproxalap did not meet its primary endpoint of improving dry eye symptoms compared to the vehicle control, despite being supportive of the drug's activity.
Regulatory Review Process: Aldeyra submitted a Clinical Study Report (CSR) as a major amendment to the NDA, and the FDA plans to communicate any proposed labeling requests by February 16, 2026, if no major deficiencies are found.
Stock Market Reaction: Following the FDA's announcement, Aldeyra Therapeutics' stock fell by 12.1% to $3.99, with a further decline of 1.5% in premarket trading.
B. Riley Financial Shares Surge Approximately 25%; Check Out 20 Stocks Making Moves in Premarket Trading
B. Riley Financial Performance: B. Riley Financial Inc reported a significant turnaround with earnings of $4.50 per share for Q2, compared to a loss of $14.35 per share a year ago, and sales increased to $225.302 million from $94.885 million, leading to a 25% rise in share price during pre-market trading.
Pre-Market Stock Movements: Several stocks experienced notable pre-market trading movements, with Biodexa Pharmaceuticals gaining 51.4% and Venus Concept surging 31.1%, while Radiopharm Theranostics saw a sharp decline of 39.8%.
Other Notable Gainers: Other stocks that rose in pre-market trading included Uniqure NV (+14.1%), Adagio Medical Holdings (+11.7%), and Sunrise New Energy (+10.5%), reflecting a mix of recovery and growth in various sectors.
Significant Losers: Stocks that faced declines included iRobot Corp, which fell 23.2% after filing for Chapter 11 bankruptcy, and Saverone 2014 Ltd, which tumbled 37.8% following a previous gain, indicating volatility in the market.
Aldeyra Shares Fall as FDA Postpones Review of Key Drug Marketing Application
FDA Review Delay: Aldeyra Therapeutics experienced a ~12% drop in premarket trading after announcing a delay in the FDA review of its resubmitted marketing application for reproxalap, with a new target action date set for March 16, 2026.
Clinical Study Report Submission: The delay follows the company's submission of a clinical study report for a dry eye disease trial, which the FDA deemed a major amendment to the new drug application (NDA).
Trial Results: The trial did not meet its primary goal of improving dry eye symptoms, and Aldeyra submitted the safety data to the FDA in August.
Prospective Labeling: Despite the delay, the FDA has provided a draft of the prospective label for reproxalap, indicating that if no major deficiencies are found, the company will receive proposed labeling requests and potential postmarketing requirements.
FDA Prolongs Review Period for Aldeyra's Reproxalap NDA for Dry Eye Disease
FDA Extension: The FDA has extended the PDUFA target action date for Aldeyra Therapeutics' NDA for reproxalap to March 16, 2026, following a major amendment related to the Clinical Study Report.
Clinical Trial Results: The field trial for reproxalap showed activity compared to a vehicle but did not meet its primary endpoint of symptom improvement, leading to the submission of additional data to the FDA.
Labeling and Requirements: The FDA provided a draft product label to Aldeyra, indicating that proposed labeling changes and potential postmarketing requirements will be communicated by February 16, 2026, if no major deficiencies are found.
Stock Performance: Aldeyra's stock closed at $3.99, down 12.11%, and further declined to $3.32 in after-hours trading, reflecting investor concerns following the news.
